The ATAD3A knockout KYSE-30 polyclonal cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ATAD3A gene in a human esophageal squamous cell carcinoma background. This product consists of a heterogeneous pool of edited cells, generated using CRISPR/Cas9-mediated gene disruption, and provides a versatile loss-of-function model for investigating ATAD3A-dependent processes in cancer biology. The polyclonal format preserves genetic diversity while enabling robust functional studies without the biases introduced by clonal selection.
The host cell line, KYSE-30, is a well-differentiated invasive esophageal squamous cell carcinoma line originally derived from a 64-year-old male patient. These malignant epithelial cells retain key characteristics of the original tumor, including invasive potential and epithelial morphology, making them a clinically relevant system for studying esophageal cancer pathogenesis. KYSE-30 cells are widely used to explore oncogenic signaling, metastatic mechanisms, and therapeutic responses, providing a physiologically appropriate context for evaluating the consequences of ATAD3A loss.
ATAD3A encodes an inner mitochondrial membrane ATPase that plays a central role in mitochondrial dynamics, cholesterol trafficking, and apoptosis regulation. The protein interacts with mitofusins MFN1 and MFN2, the cholesterol transfer protein StAR, and the endoplasmic reticulum protein WFS1 to coordinate mitochondrial fusion and cholesterol transport. Upstream, ATAD3A expression is regulated by transcription factors NRF1 and PGC-1?? in response to mitochondrial stress signals. Downstream, ATAD3A modulates DRP1-dependent mitochondrial fission, OPA1-mediated fusion, and the release of cytochrome c, thereby promoting mitochondrial network integrity and cellular survival. Disruption of ATAD3A impairs these processes, leading to fragmented mitochondria, disrupted cholesterol homeostasis, and enhanced susceptibility to intrinsic apoptosis.
In KYSE-30 esophageal cancer cells, ATAD3A knockout profoundly disrupts mitochondrial organization and cholesterol metabolism, resulting in a fragmented mitochondrial phenotype and increased apoptotic sensitivity. Given that esophageal squamous cell carcinomas often exhibit apoptosis resistance, this model is particularly valuable for dissecting how ATAD3A contributes to tumor cell survival and proliferation. The mechanistic interplay between mitochondrial dynamics and cholesterol trafficking provides a unique platform to explore metabolic vulnerabilities that may influence tumorigenic potential, with the knockout model potentially attenuating malignant properties through enhanced cell death.
This polyclonal knockout population supports a broad range of research applications, including investigations into mitochondrial dysfunction in cancer, mechanisms of apoptosis resistance, cholesterol metabolism in tumor cells, and drug sensitivity studies. Typical assays include Western blotting for apoptosis markers such as cleaved caspases and cytochrome c release, fluorescence microscopy to visualize mitochondrial morphology, cholesterol uptake and efflux assays, cell viability measurements, and migration or invasion analyses. The model is also suitable for screening therapeutic agents that target mitochondrial function or apoptosis pathways. For additional technical details or support, researchers are encouraged to contact Ascent Research.
